Endocrine Abstracts

Introduction and objective: Cardiovascular mortality is high in acromegaly. Our aim in this study was to determine the levels of the new cardiovascular marker in active acromegaly patients, the mean platelet volume (MPV) values before and after octreotide acetate long-acting repeatable treatment.

Material and methods: Thirty-six patients with active acromegaly who presented at the Endocrinology Department (mean age 46.0±14.0 years and mean BMI: 30.4±5.1 kg/m²) and 30 age- and BMI-matched (mean age 46.4±12.5 years and mean BMI: 31.7±8.1 kg/m²) healthy individuals were included in the study. All complete blood count (CBC) analysis was performed with the automatic hematology analyzer Beckman Coulter LH 750 (Beckman Coulter, USA). The platelet count (PC), MPV, platelet distribution width (PDW) and plateletcrit (PCT) were evaluated. The differences between before and after treatment values were analyzed with the paired t-test. The independent t-test was used for the comparison of patient and control groups. Relationship between variables was evaluated with Pearson’s correlation test. A P<0.05 was considered statistically significant.

Results: Serum MPV levels in acromegalic patients were not different from control subjects before treatment (7.9±0.8 and 7.9±0.9 fl respectively). Serum MPV values increased significantly in the acromegalic patients after treatment (8.3±0.9 fl, P=0.047) and differed from control subjects. MPV in acromegalic patients showing remission or cure was significantly higher than control subjects after the treatment. No statistically significant differences were found between the other parameters such as hemoglobin, platelet count, WBC count, Hgb, Hct, PCT, and PDW.